This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fessatidis, I. Th. Articles by Olsen, E.C.J. Search for Related Content PubMed PubMed Citation Articles by Fessatidis, I. Th. Articles by Olsen, E.C.J. Social Bookmarking                         What's this?

Effect of prostacyclin PGl2 on cardiopulmonary bypass- induced lung injury

Department of Cardiac Surgery, Royal Postgraduate Medical School, Hammersmith Hospital

J.J. Brannan

Department of Cardiac Surgery, Royal Postgraduate Medical School, Hammersmith Hospital

K.M. Taylor

Department of Cardiac Surgery, Royal Postgraduate Medical School, Hammersmith Hospital

M. Kanellaki-Kyparissi

Department of Histopathology, National Heart Hospital, Westmoreland Street, London

A.K. Abdulla

Department of Histopathology, National Heart Hospital, Westmoreland Street, London

E.C.J. Olsen

Department of Histopathology, National Heart Hospital, Westmoreland Street, London

Lung injury produced by cardiopulmonary bypass (CPB) is clinically characterized as postperfusion pulmonary dysfunction syndrome. The roles of humoral factors, altered perfusion modes and the occurrence of diffuse microembolism have been subjects of a number of studies. This paper presents the effectiveness of a platelet inhibiting drug, PGl₂, in preventing occlusive microaggregates in the pulmonary circulation.

In a series of experimental dog studies using a PGI₂ dosage protocol of 10 ng/kg/minute for 30 minutes prior to the onset of CPB followed by 20 mg/kg/minute during CPB, the following effects have been observed:

1) Preservation of platelet numbers during CPB (p<0.01 versus controls; n = 16).

2) Significant reduction in platelet aggregation during CPB (p <0.01; n = 16).

3) Insignificant hypotensive effect at normal levels of peripheral vascular resistance (n = 16).

4) Occlusive fibrin, leucocytes and small platelet-based microaggregates obstructing pulmonary arterioles in six of the seven control dogs but in none of the dogs receiving PGl ₂ infusion.

5) No evidence of perivascular or intra-alveolar oedema, interstitial inflammatory cell infiltrates or haemorrhage was seen in either group of dogs.

The controversy existing in relation to the possible therapeutic role of PGl₂ and, in particular, its ability to prevent occlusive microaggregates in the arterioles and capillaries of vital organs should encourage further clinical studies of PGl₂ and its derivatives during cardiac surgery.

Perfusion, Vol. 9, No. 1, 23-33 (1994)
DOI: 10.1177/026765919400900105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Asimakopoulos, P. L.C. Smith, C. P. Ratnatunga, and K. M. Taylor Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass Ann. Thorac. Surg., September 1, 1999; 68(3): 1107 - 1115. [Abstract] [Full Text] [PDF]